<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">34372914</PMID><DateCompleted><Year>2022</Year><Month>01</Month><Day>28</Day></DateCompleted><DateRevised><Year>2022</Year><Month>01</Month><Day>28</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2047-9158</ISSN><JournalIssue CitedMedium="Print"><Volume>10</Volume><Issue>1</Issue><PubDate><Year>2021</Year><Month>Aug</Month><Day>10</Day></PubDate></JournalIssue><Title>Translational neurodegeneration</Title><ISOAbbreviation>Transl Neurodegener</ISOAbbreviation></Journal><ArticleTitle>A perspective on therapies for amyotrophic lateral sclerosis: can disease progression be curbed?</ArticleTitle><Pagination><StartPage>29</StartPage><MedlinePgn>29</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">29</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s40035-021-00250-5</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease involving both upper and lower motor neurons, leading to paralysis and eventually death. Symptomatic treatments such as inhibition of salivation, alleviation of muscle cramps, and relief of spasticity and pain still play an important role in enhancing the quality of life. To date, riluzole and edaravone are the only two drugs approved by the Food and Drug Administration for the treatment of ALS in a few countries. While there is adequate consensus on the modest efficacy of riluzole, there are still open questions concerning the efficacy of edaravone in slowing the disease progression. Therefore, identification of novel therapeutic strategies is urgently needed. Impaired autophagic process plays a critical role in ALS pathogenesis. In this review, we focus on therapies modulating autophagy in the context of ALS. Furthermore, stem cell therapies, gene therapies, and newly-developed biomaterials have great potentials in alleviating neurodegeneration, which might halt the disease progression. In this review, we will summarize the current and prospective therapies for ALS.</AbstractText><CopyrightInformation>&#xa9; 2021. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Xu</LastName><ForeName>Xiaojiao</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>School of Medicine, University of Electronic Science and Technology of China, Chengdu, 610054, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Neurology, Sichuan Academy of Medical Sciences-Sichuan Provincial Hospital, Chengdu, 610031, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Shen</LastName><ForeName>Dingding</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Neurology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, 200020, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Yining</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neurology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, 200020, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Qinming</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Neurology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, 200020, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ni</LastName><ForeName>You</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neurology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, 200020, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meng</LastName><ForeName>Huanyu</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neurology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, 200020, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shi</LastName><ForeName>Hongqin</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neurology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, 200020, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Xinrui Hospital, Wuxi, 214028, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Le</LastName><ForeName>Weidong</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>School of Medicine, University of Electronic Science and Technology of China, Chengdu, 610054, China. wdle@sibs.ac.cn.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Neurology, Sichuan Academy of Medical Sciences-Sichuan Provincial Hospital, Chengdu, 610031, China. wdle@sibs.ac.cn.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Clinical Research on Neurological Diseases, the First Affiliated Hospital, Dalian Medical University, Dalian, 116021, China. wdle@sibs.ac.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Shengdi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, 200020, China. chensd@rjh.com.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Sheng</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-7428-7153</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, 200020, China. mztcs@163.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>08</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Transl Neurodegener</MedlineTA><NlmUniqueID>101591861</NlmUniqueID><ISSNLinking>2047-9158</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016166">Free Radical Scavengers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018696">Neuroprotective Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>7LJ087RS6F</RegistryNumber><NameOfSubstance UI="D019782">Riluzole</NameOfSubstance></Chemical><Chemical><RegistryNumber>S798V6YJRP</RegistryNumber><NameOfSubstance UI="D000077553">Edaravone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019468" MajorTopicYN="Y">Disease Management</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="Y">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077553" MajorTopicYN="N">Edaravone</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016166" MajorTopicYN="N">Free Radical Scavengers</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018696" MajorTopicYN="N">Neuroprotective Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019782" MajorTopicYN="N">Riluzole</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D033581" MajorTopicYN="N">Stem Cell Transplantation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">Autophagy</Keyword><Keyword MajorTopicYN="N">Gene editing</Keyword><Keyword MajorTopicYN="N">Motor neurons</Keyword><Keyword MajorTopicYN="N">Stem cells</Keyword></KeywordList><CoiStatement>Shengdi Chen is Editor-in-Chief of the journal and was not involved in the peer-review process of this article.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>2</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>7</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>8</Month><Day>10</Day><Hour>5</Hour><Minute>38</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>8</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>1</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34372914</ArticleId><ArticleId IdType="pmc">PMC8353789</ArticleId><ArticleId IdType="doi">10.1186/s40035-021-00250-5</ArticleId><ArticleId IdType="pii">10.1186/s40035-021-00250-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Oskarsson B, Gendron TF, Staff NP. Amyotrophic lateral sclerosis: an update for 2018. Mayo Clin Proc. 2018;93:1617&#x2013;28.&#xa0;</Citation><ArticleIdList><ArticleId IdType="pubmed">30401437</ArticleId></ArticleIdList></Reference><Reference><Citation>Hobson EV, McDermott CJ. Supportive and symptomatic management of amyotrophic lateral sclerosis. Nat Rev Neurol. 2016;12:526&#x2013;538. doi: 10.1038/nrneurol.2016.111.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2016.111</ArticleId><ArticleId IdType="pubmed">27514291</ArticleId></ArticleIdList></Reference><Reference><Citation>Paez-Colasante X, Figueroa-Romero C, Sakowski SA, Goutman SA, Feldman EL. Amyotrophic lateral sclerosis: mechanisms and therapeutics in the epigenomic era. Nat Rev Neurol. 2015;11:266&#x2013;279. doi: 10.1038/nrneurol.2015.57.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2015.57</ArticleId><ArticleId IdType="pubmed">25896087</ArticleId></ArticleIdList></Reference><Reference><Citation>GBD 2016 Neurology Collaborators Global, regional, and national burden of motor neuron diseases 1990&#x2013;2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2018;17:1083&#x2013;1097. doi: 10.1016/S1474-4422(18)30404-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(18)30404-6</ArticleId><ArticleId IdType="pmc">PMC6234315</ArticleId><ArticleId IdType="pubmed">30409709</ArticleId></ArticleIdList></Reference><Reference><Citation>Longinetti E, Fang F. Epidemiology of amyotrophic lateral sclerosis: an update of recent literature. Curr Opin Neurol. 2019;32:771&#x2013;776. doi: 10.1097/WCO.0000000000000730.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WCO.0000000000000730</ArticleId><ArticleId IdType="pmc">PMC6735526</ArticleId><ArticleId IdType="pubmed">31361627</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen L, Zhang B, Chen R, Tang L, Liu R, Yang Y, et al. Natural history and clinical features of sporadic amyotrophic lateral sclerosis in China. J Neurol Neurosurg Psychiatry. 2015;86:1075&#x2013;1081. doi: 10.1136/jnnp-2015-310471.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2015-310471</ArticleId><ArticleId IdType="pubmed">26124198</ArticleId></ArticleIdList></Reference><Reference><Citation>Niedermeyer S, Murn M, Choi PJ. Respiratory failure in amyotrophic lateral sclerosis. Chest. 2019;155:401&#x2013;408. doi: 10.1016/j.chest.2018.06.035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chest.2018.06.035</ArticleId><ArticleId IdType="pubmed">29990478</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonafede R, Mariotti R. ALS pathogenesis and therapeutic approaches: the role of mesenchymal stem cells and extracellular vesicles. Front Cell Neurosci. 2017;11:80. doi: 10.3389/fncel.2017.00080.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2017.00080</ArticleId><ArticleId IdType="pmc">PMC5359305</ArticleId><ArticleId IdType="pubmed">28377696</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Chalabi A, Hardiman O. The epidemiology of ALS: a conspiracy of genes, environment and time. Nat Rev Neurol. 2013;9:617&#x2013;628. doi: 10.1038/nrneurol.2013.203.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2013.203</ArticleId><ArticleId IdType="pubmed">24126629</ArticleId></ArticleIdList></Reference><Reference><Citation>Huisman MH, Seelen M, van Doormaal PT, de Jong SW, de Vries JH, van der Kooi AJ, et al. Effect of presymptomatic body mass index and consumption of fat and alcohol on amyotrophic lateral sclerosis. JAMA Neurol. 2015;72:1155&#x2013;1162. doi: 10.1001/jamaneurol.2015.1584.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2015.1584</ArticleId><ArticleId IdType="pubmed">26280944</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu X, Wang T, Chen Y, Shen Z, Gao Y, Xiao L, et al. Alcohol drinking and amyotrophic lateral sclerosis: an instrumental variable causal inference. Ann Neurol. 2020;88:195&#x2013;198. doi: 10.1002/ana.25721.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.25721</ArticleId><ArticleId IdType="pubmed">32196748</ArticleId></ArticleIdList></Reference><Reference><Citation>Sutedja NA, Veldink JH, Fischer K, Kromhout H, Wokke JH, Huisman MH, et al. Lifetime occupation, education, smoking, and risk of ALS. Neurology. 2007;69:1508&#x2013;1514. doi: 10.1212/01.wnl.0000277463.87361.8c.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000277463.87361.8c</ArticleId><ArticleId IdType="pubmed">17923612</ArticleId></ArticleIdList></Reference><Reference><Citation>van Es MA, Hardiman O, Chio A, Al-Chalabi A, Pasterkamp RJ, Veldink JH, et al. Amyotrophic lateral sclerosis. Lancet. 2017;390:2084&#x2013;2098. doi: 10.1016/S0140-6736(17)31287-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(17)31287-4</ArticleId><ArticleId IdType="pubmed">28552366</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardiman O, Al-Chalabi A, Chio A, Corr EM, Logroscino G, Robberecht W, et al. Amyotrophic lateral sclerosis. Nat Rev Dis Primers. 2017;3:17071. doi: 10.1038/nrdp.2017.71.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrdp.2017.71</ArticleId><ArticleId IdType="pubmed">28980624</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks BR. El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on Motor Neuron Diseases/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases and the El Escorial "Clinical limits of amyotrophic lateral sclerosis" workshop contributors. J Neurol Sci. 1994;124(Suppl):96&#x2013;107. doi: 10.1016/0022-510X(94)90191-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0022-510X(94)90191-0</ArticleId><ArticleId IdType="pubmed">7807156</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks BR, Miller RG, Swash M, Munsat TL. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;1:293&#x2013;299. doi: 10.1080/146608200300079536.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/146608200300079536</ArticleId><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference><Reference><Citation>Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B, et al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS study group (phase III) J Neurol Sci. 1999;169:13&#x2013;21. doi: 10.1016/S0022-510X(99)00210-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-510X(99)00210-5</ArticleId><ArticleId IdType="pubmed">10540002</ArticleId></ArticleIdList></Reference><Reference><Citation>Abe K, Itoyama Y, Sobue G, Tsuji S, Aoki M, Doyu M, et al. Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients. Amyotroph Lateral Scler Frontotemporal Degener. 2014;15:610&#x2013;617. doi: 10.3109/21678421.2014.959024.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2014.959024</ArticleId><ArticleId IdType="pmc">PMC4266079</ArticleId><ArticleId IdType="pubmed">25286015</ArticleId></ArticleIdList></Reference><Reference><Citation>Abe K, Aoki M, Tsuji S, Itoyama Y, Sobue G, Togo M, et al. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2017;16:505&#x2013;512. doi: 10.1016/S1474-4422(17)30115-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(17)30115-1</ArticleId><ArticleId IdType="pubmed">28522181</ArticleId></ArticleIdList></Reference><Reference><Citation>Imamura K, Izumi Y, Banno H, Uozumi R, Morita S, Egawa N, et al. Induced pluripotent stem cell-based drug repurposing for amyotrophic lateral sclerosis medicine (iDReAM) study: protocol for a phase I dose escalation study of bosutinib for amyotrophic lateral sclerosis patients. BMJ Open. 2019;9:e033131. doi: 10.1136/bmjopen-2019-033131.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2019-033131</ArticleId><ArticleId IdType="pmc">PMC7003406</ArticleId><ArticleId IdType="pubmed">31796494</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen PC, Hsieh YC, Huang CC, Hu CJ. Tamoxifen for amyotrophic lateral sclerosis: A randomized double-blind clinical trial. Medicine (Baltimore) 2020;99:e20423. doi: 10.1097/MD.0000000000020423.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000020423</ArticleId><ArticleId IdType="pubmed">32481440</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazzini L, Gelati M, Profico DC, Sgaravizzi G, Projetti Pensi M, Muzi G, et al. Human neural stem cell transplantation in ALS: initial results from a phase I trial. J Transl Med. 2015;13:17. doi: 10.1186/s12967-014-0371-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12967-014-0371-2</ArticleId><ArticleId IdType="pmc">PMC4359401</ArticleId><ArticleId IdType="pubmed">25889343</ArticleId></ArticleIdList></Reference><Reference><Citation>Feldman EL, Boulis NM, Hur J, Johe K, Rutkove SB, Federici T, et al. Intraspinal neural stem cell transplantation in amyotrophic lateral sclerosis: phase 1 trial outcomes. Ann Neurol. 2014;75:363&#x2013;373. doi: 10.1002/ana.24113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24113</ArticleId><ArticleId IdType="pmc">PMC4005820</ArticleId><ArticleId IdType="pubmed">24510776</ArticleId></ArticleIdList></Reference><Reference><Citation>Glass JD, Hertzberg VS, Boulis NM, Riley J, Federici T, Polak M, et al. Transplantation of spinal cord-derived neural stem cells for ALS: analysis of phase 1 and 2 trials. Neurology. 2016;87:392&#x2013;400. doi: 10.1212/WNL.0000000000002889.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000002889</ArticleId><ArticleId IdType="pmc">PMC4977116</ArticleId><ArticleId IdType="pubmed">27358335</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazzini L, Gelati M, Profico DC, Soraru G, Ferrari D, Copetti M, et al. Results from phase I clinical trial with intraspinal injection of neural stem cells in amyotrophic lateral sclerosis: a long-term outcome. Stem Cells Transl Med. 2019;8:887&#x2013;897. doi: 10.1002/sctm.18-0154.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sctm.18-0154</ArticleId><ArticleId IdType="pmc">PMC6708070</ArticleId><ArticleId IdType="pubmed">31104357</ArticleId></ArticleIdList></Reference><Reference><Citation>Oh KW, Moon C, Kim HY, Oh SI, Park J, Lee JH, et al. Phase I trial of repeated intrathecal autologous bone marrow-derived mesenchymal stromal cells in amyotrophic lateral sclerosis. Stem Cells Transl Med. 2015;4:590&#x2013;597. doi: 10.5966/sctm.2014-0212.</Citation><ArticleIdList><ArticleId IdType="doi">10.5966/sctm.2014-0212</ArticleId><ArticleId IdType="pmc">PMC4449093</ArticleId><ArticleId IdType="pubmed">25934946</ArticleId></ArticleIdList></Reference><Reference><Citation>Oh KW, Noh MY, Kwon MS, Kim HY, Oh SI, Park J, et al. Repeated intrathecal mesenchymal stem cells for amyotrophic lateral sclerosis. Ann Neurol. 2018;84:361&#x2013;373. doi: 10.1002/ana.25302.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.25302</ArticleId><ArticleId IdType="pmc">PMC6175096</ArticleId><ArticleId IdType="pubmed">30048006</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrou P, Gothelf Y, Argov Z, Gotkine M, Levy YS, Kassis I, et al. Safety and clinical effects of mesenchymal stem cells secreting neurotrophic factor transplantation in patients with amyotrophic lateral sclerosis: results of phase 1/2 and 2a clinical trials. JAMA Neurol. 2016;73:337&#x2013;344. doi: 10.1001/jamaneurol.2015.4321.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2015.4321</ArticleId><ArticleId IdType="pubmed">26751635</ArticleId></ArticleIdList></Reference><Reference><Citation>Berry JD, Cudkowicz ME, Windebank AJ, Staff NP, Owegi M, Nicholson K, et al. NurOwn, phase 2, randomized, clinical trial in patients with ALS: safety, clinical, and biomarker results. Neurology. 2019;93:2294&#x2013;2305. doi: 10.1212/WNL.0000000000008620.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000008620</ArticleId><ArticleId IdType="pmc">PMC6937497</ArticleId><ArticleId IdType="pubmed">31740545</ArticleId></ArticleIdList></Reference><Reference><Citation>Geijo-Barrientos E, Pastore-Olmedo C, De Mingo P, Blanquer M, G&#xf3;mez Espuch J, Iniesta F, et al. Intramuscular injection of bone marrow stem cells in amyotrophic lateral sclerosis patients: a randomized clinical trial. Front Neurosci. 2020;14:195. doi: 10.3389/fnins.2020.00195.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2020.00195</ArticleId><ArticleId IdType="pmc">PMC7105864</ArticleId><ArticleId IdType="pubmed">32265627</ArticleId></ArticleIdList></Reference><Reference><Citation>Thonhoff JR, Beers DR, Zhao W, Pleitez M, Simpson EP, Berry JD, et al. Expanded autologous regulatory T-lymphocyte infusions in ALS: A phase I, first-in-human study. Neurol Neuroimmunol Neuroinflamm. 2018;5:e465. doi: 10.1212/NXI.0000000000000465.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/NXI.0000000000000465</ArticleId><ArticleId IdType="pmc">PMC5961523</ArticleId><ArticleId IdType="pubmed">29845093</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller TM, Pestronk A, David W, Rothstein J, Simpson E, Appel SH, et al. An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study. Lancet Neurol. 2013;12:435&#x2013;442. doi: 10.1016/S1474-4422(13)70061-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(13)70061-9</ArticleId><ArticleId IdType="pmc">PMC3712285</ArticleId><ArticleId IdType="pubmed">23541756</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller T, Cudkowicz M, Shaw PJ, Andersen PM, Atassi N, Bucelli RC, et al. Phase 1-2 trial of antisense oligonucleotide tofersen for SOD1 ALS. N Engl J Med. 2020;383:109&#x2013;119. doi: 10.1056/NEJMoa2003715.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2003715</ArticleId><ArticleId IdType="pubmed">32640130</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaji R, Imai T, Iwasaki Y, Okamoto K, Nakagawa M, Ohashi Y, et al. Ultra-high-dose methylcobalamin in amyotrophic lateral sclerosis: a long-term phase II/III randomised controlled study. J Neurol Neurosurg Psychiatry. 2019;90:451&#x2013;457. doi: 10.1136/jnnp-2018-319294.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2018-319294</ArticleId><ArticleId IdType="pmc">PMC6581107</ArticleId><ArticleId IdType="pubmed">30636701</ArticleId></ArticleIdList></Reference><Reference><Citation>Statland JM, Moore D, Wang Y, Walsh M, Mozaffar T, Elman L, et al. Rasagiline for amyotrophic lateral sclerosis: A randomized, controlled trial. Muscle Nerve. 2019;59:201&#x2013;207. doi: 10.1002/mus.26335.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.26335</ArticleId><ArticleId IdType="pmc">PMC6545236</ArticleId><ArticleId IdType="pubmed">30192007</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludolph AC, Schuster J, Dorst J, Dupuis L, Dreyhaupt J, Weishaupt JH, et al. Safety and efficacy of rasagiline as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomised, double-blind, parallel-group, placebo-controlled, phase 2 trial. Lancet Neurol. 2018;17:681&#x2013;688. doi: 10.1016/S1474-4422(18)30176-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(18)30176-5</ArticleId><ArticleId IdType="pubmed">29934198</ArticleId></ArticleIdList></Reference><Reference><Citation>Mora JS, Genge A, Chio A, Estol CJ, Chaverri D, Hern&#xe1;ndez M, et al. Masitinib as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomized clinical trial. Amyotroph Lateral Scler Frontotemporal Degener. 2020;21:5&#x2013;14. doi: 10.1080/21678421.2019.1632346.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2019.1632346</ArticleId><ArticleId IdType="pubmed">31280619</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Chalabi A, Fang F, Hanby MF, Leigh PN, Shaw CE, Ye W, et al. An estimate of amyotrophic lateral sclerosis heritability using twin data. J Neurol Neurosurg Psychiatry. 2010;81:1324&#x2013;1326. doi: 10.1136/jnnp.2010.207464.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.2010.207464</ArticleId><ArticleId IdType="pmc">PMC2988617</ArticleId><ArticleId IdType="pubmed">20861059</ArticleId></ArticleIdList></Reference><Reference><Citation>Vandoorne T, De Bock K, Van Den Bosch L. Energy metabolism in ALS: an underappreciated opportunity? Acta Neuropathol. 2018;135:489&#x2013;509. doi: 10.1007/s00401-018-1835-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-018-1835-x</ArticleId><ArticleId IdType="pmc">PMC5978930</ArticleId><ArticleId IdType="pubmed">29549424</ArticleId></ArticleIdList></Reference><Reference><Citation>Nassif M, Valenzuela V, Rojas-Rivera D, Vidal R, Matus S, Castillo K, et al. Pathogenic role of BECN1/Beclin 1 in the development of amyotrophic lateral sclerosis. Autophagy. 2014;10:1256&#x2013;1271. doi: 10.4161/auto.28784.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/auto.28784</ArticleId><ArticleId IdType="pmc">PMC4203551</ArticleId><ArticleId IdType="pubmed">24905722</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen S, Sayana P, Zhang X, Le W. Genetics of amyotrophic lateral sclerosis: an update. Mol Neurodegener. 2013;8:28. doi: 10.1186/1750-1326-8-28.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1750-1326-8-28</ArticleId><ArticleId IdType="pmc">PMC3766231</ArticleId><ArticleId IdType="pubmed">23941283</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu H, Le WD, Xie YY, Wang XP. Current therapy of drugs in amyotrophic lateral sclerosis. Curr Neuropharmacol. 2016;14:314&#x2013;321. doi: 10.2174/1570159X14666160120152423.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1570159X14666160120152423</ArticleId><ArticleId IdType="pmc">PMC4876587</ArticleId><ArticleId IdType="pubmed">26786249</ArticleId></ArticleIdList></Reference><Reference><Citation>van Eijk RPA;&#xa0;Eijkemans MJC; Nikolakopoulos S; Jansen MD; Westeneng HJ; van Eijk KR, et al. Pharmacogenetic interactions in amyotrophic lateral sclerosis: a step closer to a cure? Pharmacogenomics J. 2020;20:220&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">31624333</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothstein JD. Edaravone: A new drug approved for ALS. Cell. 2017;171:725. doi: 10.1016/j.cell.2017.10.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2017.10.011</ArticleId><ArticleId IdType="pubmed">29100067</ArticleId></ArticleIdList></Reference><Reference><Citation>Scott A. Drug therapy: on the treatment trail for ALS. Nature. 2017;550:120&#x2013;121. doi: 10.1038/550S120a.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/550S120a</ArticleId><ArticleId IdType="pubmed">29045376</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang T, Al Khleifat A, Meurgey JH, Jones A, Leigh PN, Bensimon G, et al. Stage at which riluzole treatment prolongs survival in patients with amyotrophic lateral sclerosis: a retrospective analysis of data from a dose-ranging study. Lancet Neurol. 2018;17:416&#x2013;422. doi: 10.1016/S1474-4422(18)30054-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(18)30054-1</ArticleId><ArticleId IdType="pmc">PMC5899963</ArticleId><ArticleId IdType="pubmed">29525492</ArticleId></ArticleIdList></Reference><Reference><Citation>Zoing MC, Burke D, Pamphlett R, Kiernan MC. Riluzole therapy for motor neurone disease: an early Australian experience (1996-2002) J Clin Neurosci. 2006;13:78&#x2013;83. doi: 10.1016/j.jocn.2004.04.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jocn.2004.04.011</ArticleId><ArticleId IdType="pubmed">16410201</ArticleId></ArticleIdList></Reference><Reference><Citation>Traynor BJ, Alexander M, Corr B, Frost E, Hardiman O. An outcome study of riluzole in amyotrophic lateral sclerosis--a population-based study in Ireland, 1996-2000. J Neurol. 2003;250:473&#x2013;479. doi: 10.1007/s00415-003-1026-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-003-1026-z</ArticleId><ArticleId IdType="pubmed">12700914</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen L, Liu X, Tang L, Zhang N, Fan D. Long-term use of riluzole could improve the prognosis of sporadic amyotrophic lateral sclerosis patients: a real-world cohort study in China. Front Aging Neurosci. 2016;8:246.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5075535</ArticleId><ArticleId IdType="pubmed">27822184</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiernan MC. Motor neuron disease in 2017: Progress towards therapy in motor neuron disease. Nat Rev Neurol. 2018;14:65&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">29348545</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshino H, Kimura A. Investigation of the therapeutic effects of edaravone, a free radical scavenger, on amyotrophic lateral sclerosis (phase II study) Amyotroph Lateral Scler. 2006;7:241&#x2013;245. doi: 10.1080/17482960600881870.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17482960600881870</ArticleId><ArticleId IdType="pubmed">17127563</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi F, Takei K, Tsuda K, Palumbo J. Post-hoc analysis of MCI186-17, the extension study to MCI186-16, the confirmatory double-blind, parallel-group, placebo-controlled study of edaravone in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18:32&#x2013;39. doi: 10.1080/21678421.2017.1361442.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2017.1361442</ArticleId><ArticleId IdType="pubmed">28872914</ArticleId></ArticleIdList></Reference><Reference><Citation>Lunetta C, Moglia C, Lizio A, Caponnetto C, Dubbioso R, Giannini F, et al. The Italian multicenter experience with edaravone in amyotrophic lateral sclerosis. J Neurol. 2020;267:3258&#x2013;3267. doi: 10.1007/s00415-020-09993-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-020-09993-z</ArticleId><ArticleId IdType="pubmed">32556567</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson CE, Gronseth G, Rosenfeld J, Barohn RJ, Dubinsky R, Simpson CB, et al. Randomized double-blind study of botulinum toxin type B for sialorrhea in ALS patients. Muscle Nerve. 2009;39:137&#x2013;143. doi: 10.1002/mus.21213.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.21213</ArticleId><ArticleId IdType="pubmed">19145653</ArticleId></ArticleIdList></Reference><Reference><Citation>Pioro EP, Brooks BR, Cummings J, Schiffer R, Thisted RA, Wynn D, et al. Dextromethorphan plus ultra low-dose quinidine reduces pseudobulbar affect. Ann Neurol. 2010;68:693&#x2013;702. doi: 10.1002/ana.22093.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.22093</ArticleId><ArticleId IdType="pubmed">20839238</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersen PM, Abrahams S, Borasio GD, de Carvalho M, Chio A, Van Damme P, et al. EFNS guidelines on the clinical management of amyotrophic lateral sclerosis (MALS)--revised report of an EFNS task force. Eur J Neurol. 2012;19:360&#x2013;375. doi: 10.1111/j.1468-1331.2011.03501.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1468-1331.2011.03501.x</ArticleId><ArticleId IdType="pubmed">21914052</ArticleId></ArticleIdList></Reference><Reference><Citation>McClelland S, 3rd, Bethoux FA, Boulis NM, Sutliff MH, Stough DK, Schwetz KM, et al. Intrathecal baclofen for spasticity-related pain in amyotrophic lateral sclerosis: efficacy and factors associated with pain relief. Muscle Nerve. 2008;37:396&#x2013;398. doi: 10.1002/mus.20900.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.20900</ArticleId><ArticleId IdType="pubmed">17894358</ArticleId></ArticleIdList></Reference><Reference><Citation>Whiting PF, Wolff RF, Deshpande S, Di Nisio M, Duffy S, Hernandez AV, et al. Cannabinoids for medical use: a systematic review and meta-analysis. JAMA. 2015;313:2456&#x2013;2473. doi: 10.1001/jama.2015.6358.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2015.6358</ArticleId><ArticleId IdType="pubmed">26103030</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedman D, French JA, Maccarrone M. Safety, efficacy, and mechanisms of action of cannabinoids in neurological disorders. Lancet Neurol. 2019;18:504&#x2013;512. doi: 10.1016/S1474-4422(19)30032-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(19)30032-8</ArticleId><ArticleId IdType="pubmed">30910443</ArticleId></ArticleIdList></Reference><Reference><Citation>Riva N, Mora G, Sorar&#xf9; G, Lunetta C, Ferraro OE, Falzone Y, et al. Safety and efficacy of nabiximols on spasticity symptoms in patients with motor neuron disease (CANALS): a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Neurol. 2019;18:155&#x2013;164. doi: 10.1016/S1474-4422(18)30406-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(18)30406-X</ArticleId><ArticleId IdType="pubmed">30554828</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer T, Funke A, M&#xfc;nch C, Kettemann D, Maier A, Walter B, et al. Real world experience of patients with amyotrophic lateral sclerosis (ALS) in the treatment of spasticity using tetrahydrocannabinol:cannabidiol (THC:CBD) BMC Neurol. 2019;19:222. doi: 10.1186/s12883-019-1443-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12883-019-1443-y</ArticleId><ArticleId IdType="pmc">PMC6732193</ArticleId><ArticleId IdType="pubmed">31493784</ArticleId></ArticleIdList></Reference><Reference><Citation>Espejo-Porras F, Garc&#xed;a-Toscano L, Rodr&#xed;guez-Cueto C, Santos-Garc&#xed;a I, de Lago E, Fernandez-Ruiz J. Targeting glial cannabinoid CB(2) receptors to delay the progression of the pathological phenotype in TDP-43 (A315T) transgenic mice, a model of amyotrophic lateral sclerosis. Br J Pharmacol. 2019;176:1585&#x2013;1600. doi: 10.1111/bph.14216.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bph.14216</ArticleId><ArticleId IdType="pmc">PMC6487601</ArticleId><ArticleId IdType="pubmed">29574689</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodr&#xed;guez-Cueto C, Garc&#xed;a-Toscano L, Santos-Garc&#xed;a I, G&#xf3;mez-Almer&#xed;a M, Gonzalo-Consuegra C, Espejo-Porras F, et al. Targeting the CB(2) receptor and other endocannabinoid elements to delay disease progression in amyotrophic lateral sclerosis. Br J Pharmacol. 2021;178:1373&#x2013;1387. doi: 10.1111/bph.15386.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bph.15386</ArticleId><ArticleId IdType="pubmed">33486755</ArticleId></ArticleIdList></Reference><Reference><Citation>Urbi B, Owusu MA, Hughes I, Katz M, Broadley S, Sabet A. Effects of cannabinoids in amyotrophic lateral sclerosis (ALS) murine models: a systematic review and meta-analysis. J Neurochem. 2019;149:284&#x2013;297. doi: 10.1111/jnc.14639.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.14639</ArticleId><ArticleId IdType="pubmed">30520038</ArticleId></ArticleIdList></Reference><Reference><Citation>Bourke SC, Tomlinson M, Williams TL, Bullock RE, Shaw PJ, Gibson GJ. Effects of non-invasive ventilation on survival and quality of life in patients with amyotrophic lateral sclerosis: a randomised controlled trial. Lancet Neurol. 2006;5:140&#x2013;147. doi: 10.1016/S1474-4422(05)70326-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(05)70326-4</ArticleId><ArticleId IdType="pubmed">16426990</ArticleId></ArticleIdList></Reference><Reference><Citation>DiPALS Writing Committee, DiPALS Study Group Collaborators. Safety and efficacy of diaphragm pacing in patients with respiratory insufficiency due to amyotrophic lateral sclerosis (DiPALS): a multicentre, open-label, randomised controlled trial. Lancet Neurol. 2015;14:883&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">26234554</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonzalez-Bermejo J, Mor&#xe9;lot-Panzini C, Tanguy ML, Meininger V, Pradat PF, Lenglet T, et al. Early diaphragm pacing in patients with amyotrophic lateral sclerosis (RespiStimALS): a randomised controlled triple-blind trial. Lancet Neurol. 2016;15:1217&#x2013;1227. doi: 10.1016/S1474-4422(16)30233-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(16)30233-2</ArticleId><ArticleId IdType="pubmed">27751553</ArticleId></ArticleIdList></Reference><Reference><Citation>Oskarsson B, Moore D, Mozaffar T, Ravits J, Wiedau-Pazos M, Parziale N, et al. Mexiletine for muscle cramps in amyotrophic lateral sclerosis: A randomized, double-blind crossover trial. Muscle Nerve. 2018;58:42&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6126993</ArticleId><ArticleId IdType="pubmed">29510461</ArticleId></ArticleIdList></Reference><Reference><Citation>Adiao KJB, Espiritu AI, Bagnas MAC. Efficacy and safety of mexiletine in amyotrophic lateral sclerosis: a systematic review of randomized controlled trials. Neurodegener Dis Manag. 2020;10:397&#x2013;407. doi: 10.2217/nmt-2020-0026.</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/nmt-2020-0026</ArticleId><ArticleId IdType="pubmed">32867586</ArticleId></ArticleIdList></Reference><Reference><Citation>Kellogg J, Bottman L, Arra EJ, Selkirk SM, Kozlowski F. Nutrition management methods effective in increasing weight, survival time and functional status in ALS patients: a systematic review. Amyotroph Lateral Scler Frontotemporal Degener. 2018;19:7&#x2013;11. doi: 10.1080/21678421.2017.1360355.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2017.1360355</ArticleId><ArticleId IdType="pubmed">28799809</ArticleId></ArticleIdList></Reference><Reference><Citation>ProGas Study Group. Gastrostomy in patients with amyotrophic lateral sclerosis (ProGas): a prospective cohort study. Lancet Neurol. 2015;14:702&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4578147</ArticleId><ArticleId IdType="pubmed">26027943</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu H, Kim SH, Noh MY, Lee S, Park Y. Relationship between dietary fiber intake and the prognosis of amytrophic lateral sclerosis in Korea. Nutrients. 2020;12:3420.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7695159</ArticleId><ArticleId IdType="pubmed">33171846</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen S, Zhang X, Song L, Le W. Autophagy dysregulation in amyotrophic lateral sclerosis. Brain Pathol. 2012;22:110&#x2013;116. doi: 10.1111/j.1750-3639.2011.00546.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1750-3639.2011.00546.x</ArticleId><ArticleId IdType="pmc">PMC8029048</ArticleId><ArticleId IdType="pubmed">22150926</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X, Li L, Chen S, Yang D, Wang Y, Zhang X, et al. Rapamycin treatment augments motor neuron degeneration in SOD1(G93A) mouse model of amyotrophic lateral sclerosis. Autophagy. 2011;7:412&#x2013;425. doi: 10.4161/auto.7.4.14541.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/auto.7.4.14541</ArticleId><ArticleId IdType="pubmed">21193837</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang IF, Guo BS, Liu YC, Wu CC, Yang CH, Tsai KJ, et al. Autophagy activators rescue and alleviate pathogenesis of a mouse model with proteinopathies of the TAR DNA-binding protein 43. Proc Natl Acad Sci U S A. 2012;109:15024&#x2013;15029. doi: 10.1073/pnas.1206362109.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1206362109</ArticleId><ArticleId IdType="pmc">PMC3443184</ArticleId><ArticleId IdType="pubmed">22932872</ArticleId></ArticleIdList></Reference><Reference><Citation>Lattante S, de Calbiac H, Le Ber I, Brice A, Ciura S, Kabashi E. Sqstm1 knock-down causes a locomotor phenotype ameliorated by rapamycin in a zebrafish model of ALS/FTLD. Hum Mol Genet. 2015;24:1682&#x2013;1690. doi: 10.1093/hmg/ddu580.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddu580</ArticleId><ArticleId IdType="pubmed">25410659</ArticleId></ArticleIdList></Reference><Reference><Citation>Castillo K, Nassif M, Valenzuela V, Rojas F, Matus S, Mercado G, et al. Trehalose delays the progression of amyotrophic lateral sclerosis by enhancing autophagy in motoneurons. Autophagy. 2013;9:1308&#x2013;1320. doi: 10.4161/auto.25188.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/auto.25188</ArticleId><ArticleId IdType="pubmed">23851366</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X, Chen S, Song L, Tang Y, Shen Y, Jia L, et al. MTOR-independent, autophagic enhancer trehalose prolongs motor neuron survival and ameliorates the autophagic flux defect in a mouse model of amyotrophic lateral sclerosis. Autophagy. 2014;10:588&#x2013;602. doi: 10.4161/auto.27710.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/auto.27710</ArticleId><ArticleId IdType="pmc">PMC4091147</ArticleId><ArticleId IdType="pubmed">24441414</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Guo Y, Wang X, Yu X, Duan W, Hong K, et al. Trehalose decreases mutant SOD1 expression and alleviates motor deficiency in early but not end-stage amyotrophic lateral sclerosis in a SOD1-G93A mouse model. Neuroscience. 2015;298:12&#x2013;25. doi: 10.1016/j.neuroscience.2015.03.061.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroscience.2015.03.061</ArticleId><ArticleId IdType="pubmed">25841320</ArticleId></ArticleIdList></Reference><Reference><Citation>Fornai F, Longone P, Cafaro L, Kastsiuchenka O, Ferrucci M, Manca ML, et al. Lithium delays progression of amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A. 2008;105:2052&#x2013;2057. doi: 10.1073/pnas.0708022105.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0708022105</ArticleId><ArticleId IdType="pmc">PMC2538879</ArticleId><ArticleId IdType="pubmed">18250315</ArticleId></ArticleIdList></Reference><Reference><Citation>Fornai F, Longone P, Ferrucci M, Lenzi P, Isidoro C, Ruggieri S, et al. Autophagy and amyotrophic lateral sclerosis: the multiple roles of lithium. Autophagy. 2008;4:527&#x2013;530. doi: 10.4161/auto.5923.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/auto.5923</ArticleId><ArticleId IdType="pubmed">18367867</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo F, Liu X, Cai H, Le W. Autophagy in neurodegenerative diseases: pathogenesis and therapy. Brain Pathol. 2018;28:3&#x2013;13. doi: 10.1111/bpa.12545.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bpa.12545</ArticleId><ArticleId IdType="pmc">PMC5739982</ArticleId><ArticleId IdType="pubmed">28703923</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller RG, Jackson CE, Kasarskis EJ, England JD, Forshew D, Johnston W, et al. Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies (an evidence-based review): report of the quality standards Subcommittee of the American Academy of neurology. Neurology. 2009;73:1218&#x2013;1226. doi: 10.1212/WNL.0b013e3181bc0141.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3181bc0141</ArticleId><ArticleId IdType="pmc">PMC2764727</ArticleId><ArticleId IdType="pubmed">19822872</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller RG, Moore DH, Forshew DA, Katz JS, Barohn RJ, Valan M, et al. Phase II screening trial of lithium carbonate in amyotrophic lateral sclerosis: examining a more efficient trial design. Neurology. 2011;77:973&#x2013;979. doi: 10.1212/WNL.0b013e31822dc7a5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e31822dc7a5</ArticleId><ArticleId IdType="pmc">PMC3171956</ArticleId><ArticleId IdType="pubmed">21813790</ArticleId></ArticleIdList></Reference><Reference><Citation>Verstraete E, Veldink JH, Huisman MH, Draak T, Uijtendaal EV, van der Kooi AJ, et al. Lithium lacks effect on survival in amyotrophic lateral sclerosis: a phase IIb randomised sequential trial. J Neurol Neurosurg Psychiatry. 2012;83:557&#x2013;564. doi: 10.1136/jnnp-2011-302021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2011-302021</ArticleId><ArticleId IdType="pubmed">22378918</ArticleId></ArticleIdList></Reference><Reference><Citation>Aggarwal SP, Zinman L, Simpson E, McKinley J, Jackson KE, Pinto H, et al. Safety and efficacy of lithium in combination with riluzole for treatment of amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2010;9:481&#x2013;488. doi: 10.1016/S1474-4422(10)70068-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(10)70068-5</ArticleId><ArticleId IdType="pmc">PMC3071495</ArticleId><ArticleId IdType="pubmed">20363190</ArticleId></ArticleIdList></Reference><Reference><Citation>Morrison KE, Dhariwal S, Hornabrook R, Savage L, Burn DJ, Khoo TK, et al. Lithium in patients with amyotrophic lateral sclerosis (LiCALS): a phase 3 multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2013;12:339&#x2013;345. doi: 10.1016/S1474-4422(13)70037-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(13)70037-1</ArticleId><ArticleId IdType="pmc">PMC3610091</ArticleId><ArticleId IdType="pubmed">23453347</ArticleId></ArticleIdList></Reference><Reference><Citation>van Eijk RPA, Jones AR, Sproviero W, Shatunov A, Shaw PJ, Leigh PN, et al. Meta-analysis of pharmacogenetic interactions in amyotrophic lateral sclerosis clinical trials. Neurology. 2017;89:1915&#x2013;1922. doi: 10.1212/WNL.0000000000004606.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000004606</ArticleId><ArticleId IdType="pmc">PMC5664299</ArticleId><ArticleId IdType="pubmed">28978660</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiu SC, Chen SP, Huang SY, Wang MJ, Lin SZ, Harn HJ, et al. Induction of apoptosis coupled to endoplasmic reticulum stress in human prostate cancer cells by n-butylidenephthalide. PLoS One. 2012;7:e33742. doi: 10.1371/journal.pone.0033742.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0033742</ArticleId><ArticleId IdType="pmc">PMC3314677</ArticleId><ArticleId IdType="pubmed">22470469</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsueh KW, Chiou TW, Chiang SF, Yamashita T, Abe K, Borlongan CV, et al. Autophagic down-regulation in motor neurons remarkably prolongs the survival of ALS mice. Neuropharmacology. 2016;108:152&#x2013;160. doi: 10.1016/j.neuropharm.2016.03.035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuropharm.2016.03.035</ArticleId><ArticleId IdType="pubmed">27059126</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou QM, Zhang JJ, Li S, Chen S, Le WD. N-butylidenephthalide treatment prolongs life span and attenuates motor neuron loss in SOD1(G93A) mouse model of amyotrophic lateral sclerosis. CNS Neurosci Ther. 2017;23:375&#x2013;385. doi: 10.1111/cns.12681.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cns.12681</ArticleId><ArticleId IdType="pmc">PMC6492644</ArticleId><ArticleId IdType="pubmed">28229532</ArticleId></ArticleIdList></Reference><Reference><Citation>Schiebler M, Brown K, Hegyi K, Newton SM, Renna M, Hepburn L, et al. Functional drug screening reveals anticonvulsants as enhancers of mTOR-independent autophagic killing of M. tuberculosis through inositol depletion. EMBO Mol Med. 2015;7:127&#x2013;139. doi: 10.15252/emmm.201404137.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/emmm.201404137</ArticleId><ArticleId IdType="pmc">PMC4328644</ArticleId><ArticleId IdType="pubmed">25535254</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang JJ, Zhou QM, Chen S, Le WD. Repurposing carbamazepine for the treatment of amyotrophic lateral sclerosis in SOD1-G93A mouse model. CNS Neurosci Ther. 2018;24:1163&#x2013;1174. doi: 10.1111/cns.12855.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cns.12855</ArticleId><ArticleId IdType="pmc">PMC6489874</ArticleId><ArticleId IdType="pubmed">29656576</ArticleId></ArticleIdList></Reference><Reference><Citation>Swarup V, Phaneuf D, Dupre N, Petri S, Strong M, Kriz J, et al. Deregulation of TDP-43 in amyotrophic lateral sclerosis triggers nuclear factor kappaB-mediated pathogenic pathways. J Exp Med. 2011;208:2429&#x2013;2447. doi: 10.1084/jem.20111313.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20111313</ArticleId><ArticleId IdType="pmc">PMC3256969</ArticleId><ArticleId IdType="pubmed">22084410</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel P, Julien JP, Kriz J. Early-stage treatment with Withaferin A reduces levels of misfolded superoxide dismutase 1 and extends lifespan in a mouse model of amyotrophic lateral sclerosis. Neurotherapeutics. 2015;12:217&#x2013;233. doi: 10.1007/s13311-014-0311-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13311-014-0311-0</ArticleId><ArticleId IdType="pmc">PMC4322065</ArticleId><ArticleId IdType="pubmed">25404049</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X, Zhu F, Jiang J, Sun C, Zhong Q, Shen M, et al. Simultaneous inhibition of the ubiquitin-proteasome system and autophagy enhances apoptosis induced by ER stress aggravators in human pancreatic cancer cells. Autophagy. 2016;12:1521&#x2013;1537. doi: 10.1080/15548627.2016.1191722.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/15548627.2016.1191722</ArticleId><ArticleId IdType="pmc">PMC5082778</ArticleId><ArticleId IdType="pubmed">27308733</ArticleId></ArticleIdList></Reference><Reference><Citation>Dutta K, Patel P, Rahimian R, Phaneuf D, Julien JP. Withania somnifera reverses transactive response dna binding protein 43 proteinopathy in a mouse model of amyotrophic lateral sclerosis/frontotemporal lobar degeneration. Neurotherapeutics. 2017;14:447&#x2013;462. doi: 10.1007/s13311-016-0499-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13311-016-0499-2</ArticleId><ArticleId IdType="pmc">PMC5398980</ArticleId><ArticleId IdType="pubmed">27928708</ArticleId></ArticleIdList></Reference><Reference><Citation>Dutta K, Patel P, Julien J-P. Protective effects of Withania somnifera extract in SOD1G93A mouse model of amyotrophic lateral sclerosis. Exp Neurol. 2018;309:193&#x2013;204. doi: 10.1016/j.expneurol.2018.08.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2018.08.008</ArticleId><ArticleId IdType="pubmed">30134145</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X, Chen S, Lu K, Wang F, Deng J, Xu Z, et al. Verapamil ameliorates motor neuron degeneration and improves lifespan in the SOD1(G93A) mouse model of ALS by enhancing autophagic flux. Aging Dis. 2019;10:1159&#x2013;1173. doi: 10.14336/AD.2019.0228.</Citation><ArticleIdList><ArticleId IdType="doi">10.14336/AD.2019.0228</ArticleId><ArticleId IdType="pmc">PMC6844595</ArticleId><ArticleId IdType="pubmed">31788329</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IR, Rademakers R, Neumann M. TDP-43 and FUS in amyotrophic lateral sclerosis and frontotemporal dementia. Lancet Neurol. 2010;9:995&#x2013;1007. doi: 10.1016/S1474-4422(10)70195-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(10)70195-2</ArticleId><ArticleId IdType="pubmed">20864052</ArticleId></ArticleIdList></Reference><Reference><Citation>Marrone L, Poser I, Casci I, Japtok J, Reinhardt P, Janosch A, et al. Isogenic FUS-eGFP iPSC reporter lines enable quantification of FUS stress granule pathology that is rescued by drugs inducing autophagy. Stem Cell Reports. 2018;10:375&#x2013;389. doi: 10.1016/j.stemcr.2017.12.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stemcr.2017.12.018</ArticleId><ArticleId IdType="pmc">PMC5857889</ArticleId><ArticleId IdType="pubmed">29358088</ArticleId></ArticleIdList></Reference><Reference><Citation>Okano H, Yasuda D, Fujimori K, Morimoto S, Takahashi S. Ropinirole, a new ALS drug candidate developed using iPSCs. Trends Pharmacol Sci. 2020;41:99&#x2013;109. doi: 10.1016/j.tips.2019.12.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tips.2019.12.002</ArticleId><ArticleId IdType="pubmed">31926602</ArticleId></ArticleIdList></Reference><Reference><Citation>Imamura K, Izumi Y, Watanabe A, Tsukita K, Woltjen K, Yamamoto T, et al. The Src/c-Abl pathway is a potential therapeutic target in amyotrophic lateral sclerosis. Sci Transl Med. 2017;9:eaaf3962.</Citation><ArticleIdList><ArticleId IdType="pubmed">28539470</ArticleId></ArticleIdList></Reference><Reference><Citation>Gal J, Chen J, Barnett KR, Yang L, Brumley E, Zhu H. HDAC6 regulates mutant SOD1 aggregation through two SMIR motifs and tubulin acetylation. J Biol Chem. 2013;288:15035&#x2013;15045. doi: 10.1074/jbc.M112.431957.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M112.431957</ArticleId><ArticleId IdType="pmc">PMC3663524</ArticleId><ArticleId IdType="pubmed">23580651</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawaguchi Y, Kovacs JJ, McLaurin A, Vance JM, Ito A, Yao TP. The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress. Cell. 2003;115:727&#x2013;738. doi: 10.1016/S0092-8674(03)00939-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0092-8674(03)00939-5</ArticleId><ArticleId IdType="pubmed">14675537</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JY, Koga H, Kawaguchi Y, Tang W, Wong E, Gao YS, et al. HDAC6 controls autophagosome maturation essential for ubiquitin-selective quality-control autophagy. EMBO J. 2010;29:969&#x2013;980. doi: 10.1038/emboj.2009.405.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/emboj.2009.405</ArticleId><ArticleId IdType="pmc">PMC2837169</ArticleId><ArticleId IdType="pubmed">20075865</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen S, Zhang XJ, Li LX, Wang Y, Zhong RJ, Le W. Histone deacetylase 6 delays motor neuron degeneration by ameliorating the autophagic flux defect in a transgenic mouse model of amyotrophic lateral sclerosis. Neurosci Bull. 2015;31:459&#x2013;468. doi: 10.1007/s12264-015-1539-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12264-015-1539-3</ArticleId><ArticleId IdType="pmc">PMC5563710</ArticleId><ArticleId IdType="pubmed">26164555</ArticleId></ArticleIdList></Reference><Reference><Citation>Taes I, Timmers M, Hersmus N, Bento-Abreu A, Van Den Bosch L, Van Damme P, et al. Hdac6 deletion delays disease progression in the SOD1G93A mouse model of ALS. Hum Mol Genet. 2013;22:1783&#x2013;1790. doi: 10.1093/hmg/ddt028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddt028</ArticleId><ArticleId IdType="pubmed">23364049</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonner JF, Blesch A, Neuhuber B, Fischer I. Promoting directional axon growth from neural progenitors grafted into the injured spinal cord. J Neurosci Res. 2010;88:1182&#x2013;1192.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2844860</ArticleId><ArticleId IdType="pubmed">19908250</ArticleId></ArticleIdList></Reference><Reference><Citation>Boulis NM, Federici T, Glass JD, Lunn JS, Sakowski SA, Feldman EL. Translational stem cell therapy for amyotrophic lateral sclerosis. Nat Rev Neurol. 2011;8:172&#x2013;176. doi: 10.1038/nrneurol.2011.191.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2011.191</ArticleId><ArticleId IdType="pubmed">22158518</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen KS, Sakowski SA, Feldman EL. Intraspinal stem cell transplantation for amyotrophic lateral sclerosis. Ann Neurol. 2016;79:342&#x2013;353. doi: 10.1002/ana.24584.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24584</ArticleId><ArticleId IdType="pmc">PMC4789073</ArticleId><ArticleId IdType="pubmed">26696091</ArticleId></ArticleIdList></Reference><Reference><Citation>Zalfa C, Rota Nodari L, Vacchi E, Gelati M, Profico D, Boido M, et al. Transplantation of clinical-grade human neural stem cells reduces neuroinflammation, prolongs survival and delays disease progression in the SOD1 rats. Cell Death Dis. 2019;10:345. doi: 10.1038/s41419-019-1582-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41419-019-1582-5</ArticleId><ArticleId IdType="pmc">PMC6484011</ArticleId><ArticleId IdType="pubmed">31024007</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomsen GM, Avalos P, Ma AA, Alkaslasi M, Cho N, Wyss L, et al. Transplantation of neural progenitor cells expressing glial cell line-derived neurotrophic factor into the motor cortex as a strategy to treat amyotrophic lateral sclerosis. Stem Cells. 2018;36:1122&#x2013;1131. doi: 10.1002/stem.2825.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/stem.2825</ArticleId><ArticleId IdType="pubmed">29656478</ArticleId></ArticleIdList></Reference><Reference><Citation>Sironi F, Vallarola A, Violatto MB, Talamini L, Freschi M, De Gioia R, et al. Multiple intracerebroventricular injections of human umbilical cord mesenchymal stem cells delay motor neurons loss but not disease progression of SOD1G93A mice. Stem Cell Res. 2017;25:166&#x2013;178. doi: 10.1016/j.scr.2017.11.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.scr.2017.11.005</ArticleId><ArticleId IdType="pubmed">29154076</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazzini L, Ferrero I, Luparello V, Rustichelli D, Gunetti M, Mareschi K, et al. Mesenchymal stem cell transplantation in amyotrophic lateral sclerosis: A phase I clinical trial. Exp Neurol. 2010;223:229&#x2013;237. doi: 10.1016/j.expneurol.2009.08.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2009.08.007</ArticleId><ArticleId IdType="pubmed">19682989</ArticleId></ArticleIdList></Reference><Reference><Citation>Abati E, Bresolin N, Comi G, Corti S. Advances, challenges, and perspectives in translational stem cell therapy for amyotrophic lateral sclerosis. Mol Neurobiol. 2019;56:6703&#x2013;6715. doi: 10.1007/s12035-019-1554-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-019-1554-x</ArticleId><ArticleId IdType="pubmed">30911936</ArticleId></ArticleIdList></Reference><Reference><Citation>Garbuzova-Davis S, Shell R, Mustafa H, Hailu S, Willing AE, Sanberg PR, et al. Advancing stem cell therapy for repair of damaged lung microvasculature in amyotrophic lateral sclerosis. Cell Transplant. 2020;29:963689720913494. doi: 10.1177/0963689720913494.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0963689720913494</ArticleId><ArticleId IdType="pmc">PMC7444221</ArticleId><ArticleId IdType="pubmed">32207340</ArticleId></ArticleIdList></Reference><Reference><Citation>Thonhoff JR, Simpson EP, Appel SH. Neuroinflammatory mechanisms in amyotrophic lateral sclerosis pathogenesis. Curr Opin Neurol. 2018;31:635&#x2013;639. doi: 10.1097/WCO.0000000000000599.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WCO.0000000000000599</ArticleId><ArticleId IdType="pubmed">30048339</ArticleId></ArticleIdList></Reference><Reference><Citation>Coque E, Salsac C, Espinosa-Carrasco G, Varga B, Degauque N, Cadoux M, et al. Cytotoxic CD8(+) T lymphocytes expressing ALS-causing SOD1 mutant selectively trigger death of spinal motoneurons. Proc Natl Acad Sci U S A. 2019;116:2312&#x2013;2317. doi: 10.1073/pnas.1815961116.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1815961116</ArticleId><ArticleId IdType="pmc">PMC6369778</ArticleId><ArticleId IdType="pubmed">30674678</ArticleId></ArticleIdList></Reference><Reference><Citation>Beers DR, Zhao W, Wang J, Zhang X, Wen S, Neal D, et al. ALS patients' regulatory T lymphocytes are dysfunctional, and correlate with disease progression rate and severity. JCI Insight. 2017;2:e89530. doi: 10.1172/jci.insight.89530.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.89530</ArticleId><ArticleId IdType="pmc">PMC5333967</ArticleId><ArticleId IdType="pubmed">28289705</ArticleId></ArticleIdList></Reference><Reference><Citation>Appel SH, Engelhardt JI, Henkel JS, Siklos L, Beers DR, Yen AA, et al. Hematopoietic stem cell transplantation in patients with sporadic amyotrophic lateral sclerosis. Neurology. 2008;71:1326&#x2013;1334. doi: 10.1212/01.wnl.0000327668.43541.22.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000327668.43541.22</ArticleId><ArticleId IdType="pubmed">18936424</ArticleId></ArticleIdList></Reference><Reference><Citation>Baloh RH, Glass JD, Svendsen CN. Stem cell transplantation for amyotrophic lateral sclerosis. Curr Opin Neurol. 2018;31:655&#x2013;661. doi: 10.1097/WCO.0000000000000598.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WCO.0000000000000598</ArticleId><ArticleId IdType="pubmed">30080719</ArticleId></ArticleIdList></Reference><Reference><Citation>Beers DR, Henkel JS, Zhao W, Wang J, Appel SH. CD4+ T cells support glial neuroprotection, slow disease progression, and modify glial morphology in an animal model of inherited ALS. Proc Natl Acad Sci U S A. 2008;105:15558&#x2013;15563. doi: 10.1073/pnas.0807419105.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0807419105</ArticleId><ArticleId IdType="pmc">PMC2547419</ArticleId><ArticleId IdType="pubmed">18809917</ArticleId></ArticleIdList></Reference><Reference><Citation>Goutman SA, Savelieff MG, Sakowski SA, Feldman EL. Stem cell treatments for amyotrophic lateral sclerosis: a critical overview of early phase trials. Expert Opin Investig Drugs. 2019;28:525&#x2013;543. doi: 10.1080/13543784.2019.1627324.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/13543784.2019.1627324</ArticleId><ArticleId IdType="pmc">PMC6697143</ArticleId><ArticleId IdType="pubmed">31189354</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdul Wahid SF, Law ZK, Ismail NA, Lai NM. Cell-based therapies for amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database Syst Rev. 2019;12:Cd011742.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6920743</ArticleId><ArticleId IdType="pubmed">31853962</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Chalabi A, Brown RH., Jr Finding a treatment for ALS - will gene editing cut it? N Engl J Med. 2018;378:1454&#x2013;1456. doi: 10.1056/NEJMcibr1716741.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMcibr1716741</ArticleId><ArticleId IdType="pubmed">29641956</ArticleId></ArticleIdList></Reference><Reference><Citation>Lagier-Tourenne C, Baughn M, Rigo F, Sun S, Liu P, Li HR, et al. Targeted degradation of sense and antisense C9orf72 RNA foci as therapy for ALS and frontotemporal degeneration. Proc Natl Acad Sci U S A. 2013;110:4530&#x2013;4539. doi: 10.1073/pnas.1318835110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1318835110</ArticleId><ArticleId IdType="pmc">PMC3839752</ArticleId><ArticleId IdType="pubmed">24170860</ArticleId></ArticleIdList></Reference><Reference><Citation>Scoles DR, Pulst SM. Oligonucleotide therapeutics in neurodegenerative diseases. RNA Biol. 2018;15:707&#x2013;714.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6152438</ArticleId><ArticleId IdType="pubmed">29560813</ArticleId></ArticleIdList></Reference><Reference><Citation>Winer L, Srinivasan D, Chun S, Lacomis D, Jaffa M, Fagan A, et al. SOD1 in cerebral spinal fluid as a pharmacodynamic marker for antisense oligonucleotide therapy. JAMA Neurol. 2013;70:201&#x2013;207. doi: 10.1001/jamaneurol.2013.593.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2013.593</ArticleId><ArticleId IdType="pmc">PMC3812918</ArticleId><ArticleId IdType="pubmed">23147550</ArticleId></ArticleIdList></Reference><Reference><Citation>Selvaraj BT, Livesey MR, Zhao C, Gregory JM, James OT, Cleary EM, et al. C9ORF72 repeat expansion causes vulnerability of motor neurons to ca(2+)-permeable AMPA receptor-mediated excitotoxicity. Nat Commun. 2018;9:347. doi: 10.1038/s41467-017-02729-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-017-02729-0</ArticleId><ArticleId IdType="pmc">PMC5783946</ArticleId><ArticleId IdType="pubmed">29367641</ArticleId></ArticleIdList></Reference><Reference><Citation>Donnelly CJ, Zhang PW, Pham JT, Haeusler AR, Mistry NA, Vidensky S, et al. RNA toxicity from the ALS/FTD C9ORF72 expansion is mitigated by antisense intervention. Neuron. 2013;80:415&#x2013;428. doi: 10.1016/j.neuron.2013.10.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2013.10.015</ArticleId><ArticleId IdType="pmc">PMC4098943</ArticleId><ArticleId IdType="pubmed">24139042</ArticleId></ArticleIdList></Reference><Reference><Citation>Sareen D, O'Rourke JG, Meera P, Muhammad AK, Grant S, Simpkinson M, et al. Targeting RNA foci in iPSC-derived motor neurons from ALS patients with a C9ORF72 repeat expansion. Sci Transl Med. 2013;5:208ra149. doi: 10.1126/scitranslmed.3007529.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.3007529</ArticleId><ArticleId IdType="pmc">PMC4090945</ArticleId><ArticleId IdType="pubmed">24154603</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang J, Zhu Q, Gendron TF, Saberi S, McAlonis-Downes M, Seelman A, et al. Gain of toxicity from ALS/FTD-linked repeat expansions in C9ORF72 is alleviated by antisense oligonucleotides targeting GGGGCC-containing RNAs. Neuron. 2016;90:535&#x2013;550. doi: 10.1016/j.neuron.2016.04.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2016.04.006</ArticleId><ArticleId IdType="pmc">PMC4860075</ArticleId><ArticleId IdType="pubmed">27112497</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker LA, Huang B, Bieri G, Ma R, Knowles DA, Jafar-Nejad P, et al. Therapeutic reduction of ataxin-2 extends lifespan and reduces pathology in TDP-43 mice. Nature. 2017;544:367&#x2013;371. doi: 10.1038/nature22038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature22038</ArticleId><ArticleId IdType="pmc">PMC5642042</ArticleId><ArticleId IdType="pubmed">28405022</ArticleId></ArticleIdList></Reference><Reference><Citation>Bobbin ML, Rossi JJ. RNA interference (RNAi)-based therapeutics: delivering on the promise? Annu Rev Pharmacol Toxicol. 2016;56:103&#x2013;122. doi: 10.1146/annurev-pharmtox-010715-103633.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-pharmtox-010715-103633</ArticleId><ArticleId IdType="pubmed">26738473</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang J, Ravits J. Pathogenic mechanisms and therapy development for C9orf72 amyotrophic lateral sclerosis/frontotemporal dementia. Neurotherapeutics. 2019;16:1115&#x2013;1132. doi: 10.1007/s13311-019-00797-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13311-019-00797-2</ArticleId><ArticleId IdType="pmc">PMC6985338</ArticleId><ArticleId IdType="pubmed">31667754</ArticleId></ArticleIdList></Reference><Reference><Citation>Stoica L, Todeasa SH, Cabrera GT, Salameh JS, ElMallah MK, Mueller C, et al. Adeno-associated virus-delivered artificial microRNA extends survival and delays paralysis in an amyotrophic lateral sclerosis mouse model. Ann Neurol. 2016;79:687&#x2013;700. doi: 10.1002/ana.24618.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24618</ArticleId><ArticleId IdType="pmc">PMC5374859</ArticleId><ArticleId IdType="pubmed">26891182</ArticleId></ArticleIdList></Reference><Reference><Citation>Iannitti T, Scarrott JM, Likhite S, Coldicott IRP, Lewis KE, Heath PR, et al. Translating SOD1 gene silencing toward the clinic: a highly efficacious, off-target-free, and biomarker-supported strategy for fALS. Mol Ther Nucleic Acids. 2018;12:75&#x2013;88. doi: 10.1016/j.omtn.2018.04.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.omtn.2018.04.015</ArticleId><ArticleId IdType="pmc">PMC6023790</ArticleId><ArticleId IdType="pubmed">30195799</ArticleId></ArticleIdList></Reference><Reference><Citation>Martier R, Liefhebber JM, Garcia-Osta A, Miniarikova J, Cuadrado-Tejedor M, Espelosin M, et al. Targeting RNA-mediated toxicity in C9orf72 ALS and/or FTD by RNAi-based gene therapy. Mol Ther Nucleic Acids. 2019;16:26&#x2013;37. doi: 10.1016/j.omtn.2019.02.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.omtn.2019.02.001</ArticleId><ArticleId IdType="pmc">PMC6393708</ArticleId><ArticleId IdType="pubmed">30825670</ArticleId></ArticleIdList></Reference><Reference><Citation>Martier R, Liefhebber JM, Miniarikova J, van der Zon T, Snapper J, Kolder I, et al. Artificial microRNAs targeting C9orf72 can reduce accumulation of intra-nuclear transcripts in ALS and FTD patients. Mol Ther Nucleic Acids. 2019;14:593&#x2013;608. doi: 10.1016/j.omtn.2019.01.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.omtn.2019.01.010</ArticleId><ArticleId IdType="pmc">PMC6378669</ArticleId><ArticleId IdType="pubmed">30776581</ArticleId></ArticleIdList></Reference><Reference><Citation>Bravo-Hernandez M, Tadokoro T, Navarro MR, Platoshyn O, Kobayashi Y, Marsala S, et al. Spinal subpial delivery of AAV9 enables widespread gene silencing and blocks motoneuron degeneration in ALS. Nat Med. 2020;26:118&#x2013;130. doi: 10.1038/s41591-019-0674-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-019-0674-1</ArticleId><ArticleId IdType="pmc">PMC8171115</ArticleId><ArticleId IdType="pubmed">31873312</ArticleId></ArticleIdList></Reference><Reference><Citation>Mueller C, Berry JD, McKenna-Yasek DM, Gernoux G, Owegi MA, Pothier LM, et al. SOD1 suppression with adeno-associated virus and microrna in familial ALS. N Engl J Med. 2020;383:151&#x2013;158. doi: 10.1056/NEJMoa2005056.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2005056</ArticleId><ArticleId IdType="pubmed">32640133</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaj T, Ojala DS, Ekman FK, Byrne LC, Limsirichai P, Schaffer DV. In vivo genome editing improves motor function and extends survival in a mouse model of ALS. Sci Adv. 2017;3:eaar3952. doi: 10.1126/sciadv.aar3952.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.aar3952</ArticleId><ArticleId IdType="pmc">PMC5738228</ArticleId><ArticleId IdType="pubmed">29279867</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L, Yi F, Fu L, Yang J, Wang S, Wang Z, et al. CRISPR/Cas9-mediated targeted gene correction in amyotrophic lateral sclerosis patient iPSCs. Protein Cell. 2017;8:365&#x2013;378. doi: 10.1007/s13238-017-0397-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13238-017-0397-3</ArticleId><ArticleId IdType="pmc">PMC5413600</ArticleId><ArticleId IdType="pubmed">28401346</ArticleId></ArticleIdList></Reference><Reference><Citation>Batra R, Nelles DA, Pirie E, Blue SM, Marina RJ, Wang H, et al. Elimination of toxic microsatellite repeat expansion RNA by RNA-targeting Cas9. Cell. 2017;170:899&#x2013;912. doi: 10.1016/j.cell.2017.07.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2017.07.010</ArticleId><ArticleId IdType="pmc">PMC5873302</ArticleId><ArticleId IdType="pubmed">28803727</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinto BS, Saxena T, Oliveira R, Mendez-Gomez HR, Cleary JD, Denes LT, et al. Impeding transcription of expanded microsatellite repeats by deactivated Cas9. Mol Cell. 2017;68:479&#x2013;490. doi: 10.1016/j.molcel.2017.09.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molcel.2017.09.033</ArticleId><ArticleId IdType="pmc">PMC6013302</ArticleId><ArticleId IdType="pubmed">29056323</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrade NS, Ramic M, Esanov R, Liu W, Rybin MJ, Gaidosh G, et al. Dipeptide repeat proteins inhibit homology-directed DNA double strand break repair in C9ORF72 ALS/FTD. Mol Neurodegener. 2020;15:13. doi: 10.1186/s13024-020-00365-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-020-00365-9</ArticleId><ArticleId IdType="pmc">PMC7041170</ArticleId><ArticleId IdType="pubmed">32093728</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen HP, Van Broeckhoven C, van der Zee J. ALS genes in the genomic era and their implications for FTD. Trends Genet. 2018;34:404&#x2013;423. doi: 10.1016/j.tig.2018.03.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tig.2018.03.001</ArticleId><ArticleId IdType="pubmed">29605155</ArticleId></ArticleIdList></Reference><Reference><Citation>Veldink JH. ALS genetic epidemiology 'How simplex is the genetic epidemiology of ALS?'. J Neurol Neurosurg Psychiatry. 2017;88:537. doi: 10.1136/jnnp-2016-315469.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2016-315469</ArticleId><ArticleId IdType="pubmed">28209650</ArticleId></ArticleIdList></Reference><Reference><Citation>Cady J, Allred P, Bali T, Pestronk A, Goate A, Miller TM, et al. Amyotrophic lateral sclerosis onset is influenced by the burden of rare variants in known amyotrophic lateral sclerosis genes. Ann Neurol. 2015;77:100&#x2013;113. doi: 10.1002/ana.24306.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24306</ArticleId><ArticleId IdType="pmc">PMC4293318</ArticleId><ArticleId IdType="pubmed">25382069</ArticleId></ArticleIdList></Reference><Reference><Citation>Szeto HH. Mitochondria-targeted peptide antioxidants: novel neuroprotective agents. AAPS J. 2006;8:E521&#x2013;E531. doi: 10.1208/aapsj080362.</Citation><ArticleIdList><ArticleId IdType="doi">10.1208/aapsj080362</ArticleId><ArticleId IdType="pmc">PMC2761060</ArticleId><ArticleId IdType="pubmed">17025271</ArticleId></ArticleIdList></Reference><Reference><Citation>Cassina P, Cassina A, Pehar M, Castellanos R, Gandelman M, de Le&#xf3;n A, et al. Mitochondrial dysfunction in SOD1G93A-bearing astrocytes promotes motor neuron degeneration: prevention by mitochondrial-targeted antioxidants. J Neurosci. 2008;28:4115&#x2013;4122. doi: 10.1523/JNEUROSCI.5308-07.2008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.5308-07.2008</ArticleId><ArticleId IdType="pmc">PMC3844766</ArticleId><ArticleId IdType="pubmed">18417691</ArticleId></ArticleIdList></Reference><Reference><Citation>Miquel E, Cassina A, Mart&#xed;nez-Palma L, Souza JM, Bolatto C, Rodr&#xed;guez-Bottero S, et al. Neuroprotective effects of the mitochondria-targeted antioxidant MitoQ in a model of inherited amyotrophic lateral sclerosis. Free Radic Biol Med. 2014;70:204&#x2013;213. doi: 10.1016/j.freeradbiomed.2014.02.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.freeradbiomed.2014.02.019</ArticleId><ArticleId IdType="pubmed">24582549</ArticleId></ArticleIdList></Reference><Reference><Citation>Akaike A, Tamura Y, Sato Y, Yokota T. Protective effects of a vitamin B12 analog, methylcobalamin, against glutamate cytotoxicity in cultured cortical neurons. Eur J Pharmacol. 1993;241:1&#x2013;6. doi: 10.1016/0014-2999(93)90925-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0014-2999(93)90925-8</ArticleId><ArticleId IdType="pubmed">7901032</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X, Chen S, Li L, Wang Q, Le W. Folic acid protects motor neurons against the increased homocysteine, inflammation and apoptosis in SOD1 G93A transgenic mice. Neuropharmacology. 2008;54:1112&#x2013;1119. doi: 10.1016/j.neuropharm.2008.02.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuropharm.2008.02.020</ArticleId><ArticleId IdType="pubmed">18436268</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikeda K, Iwasaki Y, Kaji R. Neuroprotective effect of ultra-high dose methylcobalamin in wobbler mouse model of amyotrophic lateral sclerosis. J Neurol Sci. 2015;354:70&#x2013;74. doi: 10.1016/j.jns.2015.04.052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2015.04.052</ArticleId><ArticleId IdType="pubmed">25982504</ArticleId></ArticleIdList></Reference><Reference><Citation>Waibel S, Reuter A, Malessa S, Blaugrund E, Ludolph AC. Rasagiline alone and in combination with riluzole prolongs survival in an ALS mouse model. J Neurol. 2004;251:1080&#x2013;1084. doi: 10.1007/s00415-004-0481-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-004-0481-5</ArticleId><ArticleId IdType="pubmed">15372249</ArticleId></ArticleIdList></Reference><Reference><Citation>Paganoni S, Macklin EA, Hendrix S, Berry JD, Elliott MA, Maiser S, et al. Trial of sodium phenylbutyrate-taurursodiol for amyotrophic lateral sclerosis. N Engl J Med. 2020;383:919&#x2013;930. doi: 10.1056/NEJMoa1916945.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1916945</ArticleId><ArticleId IdType="pubmed">32877582</ArticleId></ArticleIdList></Reference><Reference><Citation>Paganoni S, Hendrix S, Dickson SP, Knowlton N, Macklin EA, Berry JD, et al. Long-term survival of participants in the CENTAUR trial of sodium phenylbutyrate-taurursodiol in amyotrophic lateral sclerosis. Muscle Nerve. 2021;63:31&#x2013;39. doi: 10.1002/mus.27091.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.27091</ArticleId><ArticleId IdType="pmc">PMC7820979</ArticleId><ArticleId IdType="pubmed">33063909</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang GY, Rayner SL, Chung R, Shi BY, Liang XJ. Advances in nanotechnology-based strategies for the treatments of amyotrophic lateral sclerosis. Mater Today Bio. 2020;6:100055. doi: 10.1016/j.mtbio.2020.100055.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mtbio.2020.100055</ArticleId><ArticleId IdType="pmc">PMC7280770</ArticleId><ArticleId IdType="pubmed">32529183</ArticleId></ArticleIdList></Reference><Reference><Citation>Bordoni M, Scarian E, Rey F, Gagliardi S, Carelli S, Pansarasa O, et al. Biomaterials in neurodegenerative disorders: a promising therapeutic approach. Int J Mol Sci. 2020;21:3243.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7247337</ArticleId><ArticleId IdType="pubmed">32375302</ArticleId></ArticleIdList></Reference><Reference><Citation>Bond&#xec; ML, Craparo EF, Giammona G, Drago F. Brain-targeted solid lipid nanoparticles containing riluzole: preparation, characterization and biodistribution. Nanomedicine (London) 2010;5:25&#x2013;32. doi: 10.2217/nnm.09.67.</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/nnm.09.67</ArticleId><ArticleId IdType="pubmed">20025461</ArticleId></ArticleIdList></Reference><Reference><Citation>Verma SK, Arora I, Javed K, Akhtar M, Samim M. Enhancement in the neuroprotective power of riluzole against cerebral ischemia using a brain targeted drug delivery vehicle. ACS Appl Mater Interfaces. 2016;8:19716&#x2013;19723. doi: 10.1021/acsami.6b01776.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsami.6b01776</ArticleId><ArticleId IdType="pubmed">27378322</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang T, Ferrill L, Gallant L, McGillicuddy S, Fernandes T, Schields N, et al. Verapamil and riluzole cocktail liposomes overcome pharmacoresistance by inhibiting P-glycoprotein in brain endothelial and astrocyte cells: A potent approach to treat amyotrophic lateral sclerosis. Eur J Pharm Sci. 2018;120:30&#x2013;39. doi: 10.1016/j.ejps.2018.04.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejps.2018.04.026</ArticleId><ArticleId IdType="pubmed">29704642</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin Q, Cai Y, Li S, Liu H, Zhou X, Lu C, et al. Edaravone-encapsulated agonistic micelles rescue ischemic brain tissue by tuning blood-brain barrier permeability. Theranostics. 2017;7:884&#x2013;898. doi: 10.7150/thno.18219.</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/thno.18219</ArticleId><ArticleId IdType="pmc">PMC5381251</ArticleId><ArticleId IdType="pubmed">28382161</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen L, Watson C, Morsch M, Cole NJ, Chung RS, Saunders DN, et al. Improving the delivery of SOD1 antisense oligonucleotides to motor neurons using calcium phosphate-lipid nanoparticles. Front Neurosci. 2017;11:476. doi: 10.3389/fnins.2017.00476.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2017.00476</ArticleId><ArticleId IdType="pmc">PMC5582160</ArticleId><ArticleId IdType="pubmed">28912673</ArticleId></ArticleIdList></Reference><Reference><Citation>Walczak P, Wojtkiewicz J, Nowakowski A, Habich A, Holak P, Xu J, et al. Real-time MRI for precise and predictable intra-arterial stem cell delivery to the central nervous system. J Cereb Blood Flow Metab. 2017;37:2346&#x2013;2358. doi: 10.1177/0271678X16665853.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0271678X16665853</ArticleId><ArticleId IdType="pmc">PMC5531335</ArticleId><ArticleId IdType="pubmed">27618834</ArticleId></ArticleIdList></Reference><Reference><Citation>Malysz-Cymborska I, Golubczyk D, Kalkowski L, Burczyk A, Janowski M, Holak P, et al. MRI-guided intrathecal transplantation of hydrogel-embedded glial progenitors in large animals. Sci Rep. 2018;8:16490. doi: 10.1038/s41598-018-34723-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-34723-x</ArticleId><ArticleId IdType="pmc">PMC6220305</ArticleId><ArticleId IdType="pubmed">30405160</ArticleId></ArticleIdList></Reference><Reference><Citation>Vieira S, Strymecka P, Stanaszek L, Silva-Correia J, Drela K, Fiedorowicz M, et al. Methacrylated gellan gum and hyaluronic acid hydrogel blends for image-guided neurointerventions. J Mater Chem B. 2020;8:5928&#x2013;5937. doi: 10.1039/D0TB00877J.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/D0TB00877J</ArticleId><ArticleId IdType="pubmed">32542280</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>